Clinical trial
Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists
NCT03462446 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 1, 2015
- Completion date
- May 1, 2016
- Enrollment
- 249 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.